clinical trial · NCT03118570
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Osteogenesis Imperfecta, Type IOsteogenesis Imperfecta Type IIIOsteogenesis Imperfecta Type IVsetrusumabCalciumVitamin Dzoledronic acid (optional)
brief summary
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
started
Sep 11, 2017
primary completion
Oct 1, 2019
completion
Nov 12, 2020
last updated
Jul 5, 2023
detailed description
This study was previously posted by Mereo Biopharma and was transferred to Ultragenyx in February 2021.
official title
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol